LIMINATUS PHARMA, INC. (LIMN) Current Ratio
- Current ratio · latest quarter: Value 1.12×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.12× | Current assets / current liabilities. $3.39M ÷ $3.04M ≈ 1.12× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 3.39M USD | Assets, Current |
| Current obligations | 3.04M USD | Liabilities, Current |
| Cash and equivalents | (m) | |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.39M | $3.04M | (m) | (m) | (m) | (m) | (m) | (m) | 1.12× |
| 2026-03-31 | $2.78M | $2.89M | (m) | (m) | (m) | (m) | (m) | (m) | 0.96× |
| 2025-12-31 | $500.57K | $10.30M | (m) | (m) | (m) | (m) | (m) | (m) | 0.05× |
| 2025-09-30 | $1.20M | $2.86M | (m) | (m) | (m) | (m) | (m) | (m) | 0.42× |
| 2025-06-30 | $1.78M | $10.52M | (m) | (m) | (m) | (m) | (m) | (m) | 0.17× |
| 2024-12-31 | $5.28M | $24.75M | (m) | (m) | (m) | (m) | (m) | (m) | 0.21× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |